Skip to main content
. 2022 Sep 16;9:943502. doi: 10.3389/fmed.2022.943502

FIGURE 3.

FIGURE 3

Kaplan–Meier survival analysis of death-censored graft failure for the number of dnDSA/patient after the first occurrence of the first dnDSA. Five-year death-censored allograft survival post-dnDSA: 76.6% (±2.7%) for patients with 1–2 dnDSA; 62.1% (±6.1%) for patients with 3–4 dnDSA; and 53.6% (±14.2%) for patients with > 4 dnDSA. Log-rank p = 0.008. dnDSA, de novo donor-specific antibodies.